{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:07Z","timestamp":1786119547496,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The case describes a patient with mild acute pancreatitis (AP) who developed a persistent high fever during ulinastatin treatment. This highlights the possibility of drug-induced fever, which is a rare but important adverse reaction of ulinastatin and is often overlooked in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 58-year-old male patient with mild AP had a persistent high fever during the treatment with ulinastatin, but there was no evidence of infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Mild AP, ulinastatin-related drug fever.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The initial conservative treatment for AP included fasting, rehydration and taking ulinastatin. Antibiotics (ceftriaxone, later changed to imipenem) were used for suspected infection. After excluding infection, ulinastatin was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Within 48 hours of stopping ulinastatin, the patient\u2019s fever symptoms were relieved and his subsequent condition stabilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights the importance of considering drug-induced fever in clinical practice. Recognizing it promptly and discontinuing the drug can prevent unnecessary interventions and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046808","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:01:57Z","timestamp":1767711717000},"page":"e46808","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fever in a patient with mild acute pancreatitis caused by ulinastatin injection: A case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Tong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linzhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-6156","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcrc.2018.01.021","article-title":"Role of ulinastatin, a trypsin inhibitor, in severe acute pancreatitis in critical care setting: a retrospective analysis.","volume":"45","author":"Lagoo","year":"2018","journal-title":"J Crit Care"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11096-018-0625-9","article-title":"Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea.","volume":"40","author":"Han","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"95","DOI":"10.37737\/ace.23013","article-title":"Drug fever: a narrative review.","volume":"5","author":"Someko","year":"2023","journal-title":"Ann Clin Epidemiol"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"17979","DOI":"10.1038\/s41598-022-22341-7","article-title":"The combination of ulinastatin and somatostatin reduces complication rates in acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Horv\u00e1th","year":"2022","journal-title":"Sci Rep"},{"key":"R5-20260218","article-title":"Effect of ulinastatin combined with somatostatin on inflammatory markers, hemodynamics and immune cells in the treatment of severe pancreatitis [published online ahead of print June 21, 2024].","author":"Yang","journal-title":"Altern Ther Health Med"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00134-014-3278-8","article-title":"Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study.","volume":"40","author":"Karnad","year":"2014","journal-title":"Intensive Care Med"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40360-022-00585-3","article-title":"Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.","volume":"23","author":"Li","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"e0177425","DOI":"10.1371\/journal.pone.0177425","article-title":"Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: a randomized, double-blind, placebo-controlled, ascending-dose study.","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:52Z","timestamp":1786041232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046808","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}